In the streptozotocin-nicotinamide diabetic mouse or rat, rodent models for type 2 diabetes, dipeptidyl peptidase IV inhibition improved hemoglobin A1C levels, glucose intolerance, and lipid profiles and increased GLP-1 levels [30, 31]. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.